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Graves’ disease is a most common cause of hyperthyroidism. It is an autoimmune disease, and autoimmune process induces
an inﬂammatory reaction, and reactive oxygen species (ROSs) are among its products. When balance between oxidants and
antioxidants is disturbed, in favour of the oxidants it is termed “oxidative stress” (OS). Increased OS characterizes Graves’ disease.
It seems that the level of OS is increased in subjects with Graves’ ophthalmopathy compared to the other subjects with Graves’
disease. Among the other factors, OS is involved in proliferation of orbital ﬁbroblasts. Polymorphism of the 8-oxoG DNA N-
glycosylase 1 (hOGG1) involved in repair of the oxidative damaged DNA increases in the risk for developing Grave’s disease.
Treatment with glucocorticoids reduces levels of OS markers. A recent large clinical trial evaluated eﬀe c to fs e l e n i u mo nm i l d
Graves’ ophthalmopathy. Selenium treatment was associated with an improved quality of life and less eye involvement and slowed
the progression of Graves’ orbitopathy, compared to placebo.
1.Introduction
Graves’ disease is a most common cause of hyperthyroidism
in iodine suﬃcient areas [1]. It is characterized by diﬀuse
goitre and hyperthyroidism. Graves’ orbitopathy represents
orbit involvement and is clinically relevant in about half
of the patients with the Graves’ disease. In 3 to 5% of the
patients, orbitopathy is severe [2]. Graves’ disease is an auto-
immune disease characterized by the presence of the serum
autoantibodies. TSH receptor antibody represents the major
autoantibody in Graves’ disease [3].
Autoimmune process induces an inﬂammatory reaction
and reactive oxygen species (ROSs) are among its products.
ROSs are formed as normal metabolic products and are
important in normal cellular functioning, but their produc-
tion can be increased under pathological conditions and
cause damage [4, 5]. Therefore, a large number of antioxi-
dant systems act as protective mechanism. Among them are
superoxide dismutase which catalyses dismutation of super-
oxidetoperoxide,catalasewhichcatalysesthedecomposition
of hydrogen peroxide to water and oxygen, while glutathione
peroxidise which reduces lipid hidroperoxides while simulta-
neouslyoxidizing glutathione[6].Situationinwhichbalance
between oxidants and antioxidants is disturbed in favour of
the oxidants is termed “oxidative stress” (OS) [4].
2. OxidativeStress andthe Thyroid Gland
Synthesis of thyroid hormones requires formation of the
hydrogen peroxide, a highly reactive oxidant. Hydrogen per-
oxide and oxidized iodine are immediately used in per-
oxidation reaction that is catalysed by thyroid peroxidase
[7]. To protect thyroid cells from reactive oxygen species
(ROSs) a potent antioxidant system exists in thyroid. Per-
oxiredoxin,glutathioneperoxidase,thioredoxin,andcatalase
are involved in this antioxidant system [8]. Peroxiredoxins
belong to a family of antioxidant proteins that are well
conserved during evolution. Peroxiredoxin 5 (PRDX5) is ex-
pressed in the thyroid, mostly in the cytoplasm. The level
of expression is correlated with the functional status of
thyroid cells, being higher in multinodular goitres, and even
higher in hyperthyroid tissues [9]. Catalase and glutathione
peroxidases are also increased in hyperthyroid tissues [10].
Some level of oxidative load is necessary for thyroid
function and proliferation. In a healthy thyroid, ROSs are2 Journal of Thyroid Research
produced in an area that is located at the apical pole of the
cell in microvilli, where H2O2 is consumed either during the
hormonesynthesisorbyantioxidantsystems.However,Th1-
induced ROS production causes ROS accumulation both in
the cytoplasm and in nuclei, where it can become toxic.
Interestingly, in vivo, both the antioxidant N-acetylcysteine
(NAC) and the anti-inﬂammatory prostaglandin 15deoxy-
12,14-prostaglandinJ2(15dPGJ2)protectthethyroidagainst
toxic eﬀects of the OS. It seems that NAC and 15dPGJ2
mainly act on inﬁltrating inﬂammatory cells, reducing the
extrafollicular ROS load [11]. As hydrogen peroxide and
iodine are cosubstrates in thyroid hormone production,
iodine inhibits hydrogen peroxide production [12]. Tobacco
smoke contains thyocyanate that blocks iodine transport
into thyrocite. This could increase H2O2 production and
oxidative load, especially when associated with other envi-
ronmental factors [13, 14].
Poncin and coworkers suggested that thyroid interstitial
inﬂammation depends on the balance of the OS and the
antioxidative defences (AODs). In basal, healthy conditions,
both OS and AOD are low, and there is no inﬂammation.
IncreaseinOSbalancedbytheincreaseinAODwouldleadto
minimalinﬂammation,butunopposedincreaseinOSwould
lead to strong inﬂammation and cell necrosis. Reducing
OS would lead to inﬂammation reduction and vice versa
[11, 15].
3. OxidativeStressinGraves’ Diseaseand
Peripheral Tissues
Graves’ disease is characterized by increased oxidative stress.
Abalovich at all found increased markers of OS and decrease
in markers of AOD in erythrocytes of patients with Graves’
disease. Allanalysedmarkersnormalized wheneuthyroidism
was achieved after treatment with methimazole. However,
after treatment with radioactive iodine, levels of tert-butyl
hydroperoxide initiated chemiluminiscence and superoxide
dismutase levels did not normalize [16]. Increased markers
of OS were found in plasma of Graves’ disease patients, even
when they are rendered euthyroid. Levels of OS and AOD
markers were higher, both in plasma and in thyroid tissue in
patients whose treatment was shorter than 6 months [17].
However, thyroid hormones, per se, induce OS, which is
tissue and species speciﬁc [18]. Even in subclinical hyperthy-
roidism, oxidative stress and antioxidative response seem to
be increased [19]. It seems that the oxidative stress-induced
activation of the NF-kappaB pathway might play a role
in the autoimmune response in hyperthyroidism [20, 21].
Therefore, when antioxidant supplementation is added to
methimazole, euthyroidism is more rapidly achieved [22].
However, it seems that the level of OS is increased in subjects
withGraves’ophthalmopathycomparedtotheothersubjects
with the Graves’ disease. Methimazole treatment normalizes
markers of oxidative stress in plasma in subject with Graves’
disease, but not in subjects with Graves’ ophthalmopathy
[23].
Hyperthyroidism is associated with increased lipid per-
oxidationproductsinratliverandwithincreasedactivitiesof
glutathione peroxidase, superoxide dismutase, and catalase
in the liver [24]. Liver oxidative stress increases quickly after
increase of thyroid hormones [25]. In rat kidney and testis,
hyperthyroidism is associated with increased oxidative stress
and lipid peroxidation [26–28].
Hyperthyroidism is also associated with increased oxida-
tive stress and oxidative damage to lipids and genomic DNA
in the aortic wall [29]. During hyperthyroidism, there is an
increase in myocardial oxidative stress that is associated with
lipid peroxidation and protein oxidation. Myocardial antiox-
idant enzyme activities elevation accompanied by protein
expression induction occurs after four weeks of hyperthy-
roidism[30].Itseemsthatoxidativestressplaysanimportant
role in cardiac hypertrophy, by the redox activation of AKT1
and JUN/FOS signaling pathways [31]. Redox imbalance
due to hyperthyroidism induces adaptation of antioxidant
systems, also inducing ERK1/2 activation and leading to
development of cardiac hypertrophy [32]. It is interesting to
notethatalthoughlong-termthyroxinadministration causes
cardiac hypertrophy, it is also associated with enhanced
tolerance of the myocardium to ischemia and reperfusion.
This response may involve the thyroid hormone-induced
upregulation of HSP70 [33]. In skeletal muscle, hyperthy-
roidism causes increased oxidative stress associated with
oxidative modiﬁcation in myosin heavy chain causing the
decrease in force production [34].
4. OxidativeStress inGraves’Diseaseand
RetroorbitalTissues
Graves’ orbitopathy is caused by inﬂammation in the orbital
connective tissue. Enhanced adipogenesis and overproduc-
tion of glycosaminoglycans causes an increase in orbital
volume and ﬁbrosis of the extraocular muscles [35]. Among
the other factors, OS is involved in proliferation of orbital
ﬁbroblasts.Inorbitalﬁbroblasts,obtainedfromsubjectswith
severe grave orbitopathy, superoxide radicals induce a dose-
dependent cellular proliferation. This eﬀect is not observed
in ﬁbroblast cultures obtained from control subjects [36].
However, superoxide-induced ﬁbroblast proliferation could
be prevented by methimazole, the xanthine oxidase inhibitor
allopurinol, and nicotinamide [36, 37]. In orbital tissue
samples, there is increased level of lipid hydroxyperox-
ide, superoxide dismutase, glutathione peroxidise, and glu-
tathionereductaseinGraves’orbitopathypatients,compared
to controls. Furthermore, there is strong negative correlation
between the ophthalmopathy index and glutathione level
[38].
IL-1β is produced by activated macrophages and is an
important mediator of the inﬂammatory response. Add-
ing IL-1β to cultures of retroorbital ﬁbroblasts causes an
increased oxygen-free radical production in a dose-depend-
ent manner. This is observed both in Graves’ and in control
cultures. Total intracellular superoxide dismutase (SOD)
activity was stimulated by IL-1β, both in control and in
Graves’ cultures. However, in Graves’ cultures SOD activity
was increased at rest and less responsive to IL-1β stimula-
tion. IL-1β was a potent stimulator of glycosaminoglycanJournal of Thyroid Research 3
(GAG) accumulation in both normal and GO retroocular
ﬁbroblasts. IL-1β signiﬁcantly stimulated the GAG synthesis
in both normal and Graves’ ﬁbroblasts cells in a dose-de-
pendent manner. Adding SOD and catalase partially blocked
accumulation of the GAG induced by IL-1β [39].
HSP72 is a stress inducible form of cytosolic HSP70. Its
expression is induced by the environmental stress, such as
heat shock, anoxia, and ischemia. HSP72 has cytoprotective
eﬀects and functions as a molecular chaperone in protein
folding, transport, and degradation. Moreover, HSP72 can
inhibit apoptosis by several diﬀerent mechanisms. In addi-
tion,HSPsarepotentactivatorsoftheinnateimmunesystem
and they stimulate the production of proinﬂammatory
cytokines. In retroorbital ﬁbroblasts obtained from GO
patients, both H2O2 and heat stress signiﬁcantly increased
HSP72 expression. Antioxidants, methimazole, and PTU
reduced H2O2-induced HSP72 expression, and to a lesser
degree heat-induced HSP72 expression [40–42].
Oxidative DNA damage was found to be signiﬁcantly
elevated in cultured orbital ﬁbroblasts, but only slightly
increased in ﬁbroadipose tissues of patients with Graves’ or-
bitopathy. In patients with Graves’ orbitopathy, there was
signiﬁcant correlation between TSH receptor antibody levels
and 8-hydroxy-2-deoxyguanosine (a biomarker of DNA
damage) content [43]. The presence of oxidative stress
parameters in cultured orbital ﬁbroblasts and its correlation
with TSH receptor antibody levels represents a good indica-
tion that oxidative stress exerts action in GO.
Urinary 8-hydroxy-2-deoxyguanosine (8-OhdG) is also
a marker of oxidative DNA damage. The study by Tsai et al.
found that the urinary level of 8-OHdG was signiﬁcantly
increased in GO patients (1.9-fold compared with normal
subjects). This increase was pronounced in patients with
active GO (2.4-fold compared with normal subjects). More-
over, urinary 8-OhdG level signiﬁcantly correlated with both
clinical activity score and ophthalmopathy index. However,
this association becomes nonsigniﬁcant after adjustment for
other parameters, particularly the smoking status. It should
be noted that smoker had higher urinary 8-OhdG level than
never-smokers, and that smoking was signiﬁcant factor in
multivariate analysis [44]. It is well known, from epidemi-
ological studies, that strong evidence for a causal association
between smoking and development of Graves’ orbitopathy
exists [45]. Study by Tsai et al. implies that smoking-induced
oxidative stress contributes to the pathogenesis of Graves’
orbitopathy [44].
One of the major forms of DNA damage induced by
OS is 7, 8-dihydro-8-oxoguanine, referred in an abbreviated
way as 8-oxoguanine (8-oxoG). This type of DNA damage is
repaired by the base excision repair pathway. This pathway is
initiated by the recognition and excision of the oxidized gua-
nine by a DNA glycosylase. In humans, the major glycosylase
is 8-oxoG DNA N-glycosylase 1 (hOGG1). The hOGG1 is
located on chromosome 3p25/26 and is highly polymorphic.
The C to G substitution at position 1245 in exon 7 results
in substitution of serine with cysteine in codon 326 has
been associated with a reduced capacity to repair oxidative
DNA damage. Tanrikulu et al. assessed hOGG1 Ser326Cys
polymorphism (rs1052133) asacandidate risk factorforGD.
They found that Cys/Cys genotype had a 3.5-fold (95% CI:
2.10–6.01, P<0.001) and the Cys allele had 1.83-fold (95%
CI: 1.43–2.34, P<0.001) increase in the risk for developing
Grave’s disease in their population [46]. The Ser326Cys
polymorphism in hOGG1 gene was shown to reduce the
hOGG1 activity in both in vitro and in vivo studies [46]. As
the production of 8-oxoG is increased both in retroorbital
ﬁbroblasts and in urine of patients with GD and correlates
with the disease activity, it could be argued that reduced
hOGG1activitycausesincreasedDNAdamageandincreased
OS making subject more susceptible to development of
Graves’ orbitopathy [43, 44].
5. AntioxidantsasTreatmentforGraves’Disease
Treatment of the Graves’ disease reduces OS both by
rendering patients euthyroid and by the direct eﬀect of
antithyroid drugs, particularly methimazole, on OS. Methi-
mazole completely normalized parameters of OS in periph-
eral erythrocytes, while radioactive iodine did not [16].
In cultured ﬁbroblasts methimazole prevented superoxide-
induced ﬁbroblast proliferation, while propylthiouracil had
little eﬀect [36]. Other forms of treatment for Graves’ disease
also inﬂuence parameters of OS. In euthyroid patients treat-
ment of Graves’ ophthalmopathy with oral glucocorticoids
signiﬁcantly reduced urinary level of 8-OhdG (a marker
of oxidative DNA damage). It was noted that in patients
who had recurrence of GO urinary level of 8-OhdG was
high [47]. In the study by Akarsu et al. serum levels of serum
level malondialdehyde (MDA, a product of ROS degra-
dation of degrade polyunsaturated lipids) were higher in
patients with GO, compared to controls and Graves’ disease
patients without GO. On the other hand, level of glutathione
(GSH, a nonenzymatic antioxidant) was decreased in GO
patients. Treatment with intravenous or oral methylpred-
nisolone reduced MDA level. However, intravenous methyl-
prednisolone induced more rapid therapeutic response and
more rapid reduction in MDA level (in 4 weeks). Twelve
weeks after the end of the treatment, clinical activity score
and serum level of MDA were the same in both methyl-
prednisolone-treated groups [48].
Treatment of Graves’ disease with antioxidants is based
on a premise of role of the OS in its’ pathogenesis. A small
trial using allopurinol and nicotinamide showed eﬀective-
ness of antioxidant treatment of mild and moderately severe
Graves’ ophthalmopathy [49].
Selenium is a trace element and is essential for seleno-
proteins synthesis where selenium functions as a redox cen-
tre. Some of selenoproteins like thioredoxin reductase and
glutathione peroxidases play the key role in antioxidative
defences. Most of the European countries are selenium deﬁ-
cient [50]. Previous clinical trials showed some eﬀect of sele-
nium on thyroid autoimmunity [51]. A recent large clinical
trial evaluated eﬀect of selenium on mild Graves’ ophthal-
mopathy. Patients from several European countries were
treated with sodium selenite in a dose of 100μg twice daily.
Selenium treatment was associated with an improved quality4 Journal of Thyroid Research
of life and less eye involvement and slowed the progression
of Graves’ orbitopathy, compared to placebo [52].
6. Concluding Remarks
Evidence from previous studies suggests that oxidative stress
plays a role in the pathogenesis of Graves’ disease. In vitro
and in vivo studies showed that antithyroid drugs and
antioxidants inﬂuence parameters of oxidative stress both in
retroorbitaltissueandinthewholeorganism.However,until
recently, all studies were small, nonrandomized, or uncon-
trolled, and large, controlled study was asked for [53]. Now,
a large, randomized, controlled study proved that selenium
supplementation signiﬁcantly improves quality of life and
reduces ocular involvement in patients with mild Graves’
orbitopathy. Although it seems that antioxidative therapy
will not play a major role in the treatment of Graves’ disease,
further trials are necessary to deﬁne its place as adjunctive
therapy, or as the therapy for mild and moderate Graves’
ophthalmopathy.
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